Therapy Areas: Oncology
AbbVie licenses PD-1/VEGF bispecific antibody RC148 from RemeGen in multi-billion dollar oncology deal
12 January 2026 - Oncology company AbbVie (NYSE: ABBV) and biopharmaceutical company RemeGen announced on Monday that the companies have entered into an exclusive licensing agreement for the developme...
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
12 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has entered into a clinical trial collaboration with biopharmaceutical company GS...
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
12 January 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has submitted a Biologics License Application to the US Food and Drug Administrat...
Phanes Therapeutics reports clinical data on spevatamig chemotherapy combination in frontline treatment of mPDAC
12 January 2026 - Phanes Therapeutics Inc, a California-based clinical stage biotech company focused on innovative drug discovery and development in oncology, on Friday reported the first clinical dat...
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
9 January 2026 - Acousia Therapeutics GmbH, a clinical-stage biotechnology company based in Germany, announced on Thursday that it has completed patient enrolment in its Phase 2 PROHEAR clinical study...
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
9 January 2026 - Clinical-stage life sciences company ZYUS Life Sciences Corporation (TSXV:ZYUS) on Thursday reported favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatmen...